F-star bags third Takeda tie-up in a year with multi-specific antibodies for cancer
The stars have aligned for the third time between invoX Pharma’s F-star and Takeda as the duo gets to work on another antibody pact, with an aim to create new immunotherapies for undisclosed cancers.
The new partnership centers around multi-specific antibodies using F-star’s so-called Fcab and tetravalent monoclonal antibody platforms, and it follows deals around bispecific antibodies that the companies made in July 2022 and in March.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
